Financials in USD. Standardized financial statements.
A compact view of how Rigel Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $294.28M | $179.28M | $116.88M | $120.24M | $149.24M | $108.62M | $59.29M | $44.51M | $4.48M | $20.38M |
| Revenue Growth? | +64.1% | +53.4% | -2.8% | -19.4% | +37.4% | +83.2% | +33.2% | +892.6% | -78.0% | 0.0% |
| Cost of Revenue? | $19.62M | $18.65M | $7.11M | $1.75M | $1.08M | $895,000 | $906,000 | $287,000 | $46.27M | $63.45M |
| Gross Profit? | $274.66M | $160.63M | $109.77M | $118.49M | $148.15M | $107.73M | $58.38M | $44.22M | -$41.78M | -$43.06M |
| Gross Margin? | +93.3% | +89.6% | +93.9% | +98.5% | +99.3% | +99.2% | +98.5% | +99.4% | -931.9% | -211.3% |
| Operating Expenses? | $149.19M | $136.44M | $130.26M | $174.04M | $160.65M | $136.70M | $127.47M | $116.91M | $84.10M | $90.12M |
| Operating Income? | $125.47M | $24.19M | -$20.49M | -$55.55M | -$12.50M | -$28.97M | -$69.09M | -$72.68M | -$79.62M | -$69.74M |
| EBITDA? | $131.56M | $28.51M | -$16.98M | -$53.87M | -$11.29M | -$27.68M | -$65.88M | -$69.89M | -$77.53M | -$63.03M |
| Income Before Tax | $121.83M | $18.37M | -$25.09M | -$58.57M | -$17.31M | -$29.74M | -$66.89M | -$70.48M | -$77.99M | -$69.22M |
| Income Tax Expense | -$245.20M | $881,000 | $0 | $0 | $605,000 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | $367.02M | $17.48M | -$25.09M | -$58.57M | -$17.91M | -$29.74M | -$66.55M | -$70.48M | -$77.99M | -$69.22M |
| EPS? | $20.40 | $0.99 | $-1.44 | $-3.40 | $-1.10 | $-1.80 | $-4.00 | $-4.40 | $-6.17 | $-7.33 |
| Diluted EPS? | $19.48 | $0.99 | $-1.44 | $-3.40 | $-1.10 | $-1.80 | $-4.00 | $-4.40 | $-6.17 | $-7.33 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality